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O B J E C T I V E S The aim of this study was to use angiography and grayscale and intravascular ultrasound–
virtual histology to assess coronary lesions that caused events during a median follow-up period of 3.4 years.
B A C KG ROUND Vulnerable plaque-related events are assumed to be the result of substantial
progression of insigniﬁcant lesions.
METHOD S In the PROSPECT (Providing Regional Observations to Study Predictors of Events in the
Coronary Tree) study, 697 patients with acute coronary syndromes underwent treatment of all culprit lesions
followed by 3-vessel imaging to assess the natural history of culprit and untreated nonculprit (NC) lesions.
Future adverse cardiovascular events adjudicated to NC lesions were divided into those with versus without
substantial lesion progression (SLP) (20% angiographic diameter stenosis increase).
R E S U L T S NC lesion events occurred in 72 patients, 44 (61%) with and 28 (39%) without SLP. Myocardial
infarctions (n  6) occurred only in patients with SLP. Conversely, patients without SLP presented only with
unstable or increasing angina requiring rehospitalization. Lesions with versus without SLP occurred later
(median time to event 401 vs. 223 days, p  0.07); were less severe at baseline (median diameter stenosis
26.4% vs. 53.8%, p  0.0001) but more severe at the time of the event (mean diameter stenosis 73.8% vs.
56%, p  0.0001); and had comparable baseline median plaque burden (68.7% vs. 70.1%, p  0.17),
minimum luminal area (3.7 vs. 4.0 mm2, p 0.60), and intravascular ultrasound–virtual histology phenotype
(83.3% vs. 90.9%, p  0.68; classiﬁed as ﬁbroatheromas at baseline).
CONC L U S I O N S NC lesions responsible for future cardiovascular events showed angiographic
increase during 3.4 years of follow-up, whereas SLP underlay many but not all of them. NC events due
to lesions with SLP were angiographically less severe and presented with a delayed time course but were
otherwise indistinguishable from NC events that were not associated with SLP. (J Am Coll Cardiol Img
2012;5:S95–105) © 2012 by the American College of Cardiology Foundation
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S96ost cases of sudden cardiac death and
myocardial infarction (MI) are believed
to arise from plaque rupture or surface
erosion with subsequent thrombotic cor-
nary occlusion of angiographically mild lesions (“vul-
erable plaques”). The thin-cap fibroatheroma
TCFA), a metabolically active lesion with a large
ipid-rich necrotic core and thin fibrous cap, is re-
arded as the most common type of rupture-prone
See page S106
and thrombosis-prone plaque (1–7). Angiographically,
such lesions frequently undergo rapid progression in
stenosis severity after plaque rupture, which may result in
a spectrum of syndromes, ranging from sudden coronary
occlusion with catastrophic symptoms to asymptomatic
plaque progression (8–10).
The PROSPECT (Providing Regional
Observations to Study Predictors of Events in
the Coronary Tree) study investigated the
natural history of atherosclerosis using multi-
modality intravascular imaging in vivo in pa-
tients presenting with acute coronary syn-
drome (ACS) (11–18). After treating all
responsible culprit lesions, coronary angiogra-
phy of the entire coronary tree and grayscale
and radiofrequency intravascular ultrasound
(IVUS)–virtual histology (VH) imaging of the
proximal 6 to 8 cm of all 3 coronary arteries
was performed, after which patients were fol-
lowed for a median of 3.4 years on optimal
medical therapy. Angiography was repeated in
patients who had events during the
follow-up period. Baseline and event-related
coronary angiograms were compared to
identify lesions responsible for unanticipated future
events, which could occur either at the site of original
treatment (culprit lesion–related events) or at un-
treated sites (nonculprit [NC] lesions). No prior study
has examined how frequently future adverse cardio-
vascular events are indeed associated with angio-
graphic substantial lesion progression (SLP) from NC
lesions. We therefore sought to assess the frequency
and predictors of angiographic SLP (the classic vul-
nerable plaque as defined by Naghavi et al. [19,20])
leading to NC lesion–related events in the contempo-
rary era after the interventional management of ACS.
M E T H O D S
Study population. In the PROSPECT study, 697
und
maatients with ACS (unstable angina with electro-ardiographic changes, non–ST-segment elevation
I, or recent ST-segment elevation MI) were
nrolled from 37 sites in the U.S. and Europe. The
tudy was approved by the institutional review
oards of the participating institutions, and written
nformed consent was obtained from all patients.
he pre-specified primary end point was the occur-
ence of major adverse cardiac events (MACEs),
he composite of cardiac death, cardiac arrest, MI,
r rehospitalization due to unstable or progressive
ngina. On the basis of follow-up angiography,
vents were adjudicated as occurring at initially
reated sites (culprit lesions) or at previously un-
reated coronary segments (NC lesions). If follow-up
ngiography was not performed, the location was
lassified as indeterminate.
Coronary angiography. All baseline angiograms
were prospectively analyzed without knowledge of
subsequent events. Angiographic qualitative and
quantitative analysis of the entire coronary tree was
performed at the Angiographic Core Laboratory of
the Cardiovascular Research Foundation (New York,
New York) using proprietary methods modified
from Medis CMS software version 7.0 (Medis
Medical Imaging Systems, Leiden, the Nether-
lands). Every 1.5 mm of vessel length, the reference
diameter, minimal luminal diameter, and diameter
stenosis (DS) were recorded. Analysis of all angio-
graphic lesions with 30% visual DS was also
pre-specified. NC lesions were divided into those
with and those without SLP, prospectively defined
as a 20% increase in the quantitative coronary
angiographic DS between baseline and follow-up.
Grayscale and IVUS-VH imaging and analyses. Gray-
scale and radiofrequency IVUS of the left main and
proximal 6 to 8 cm of each major epicardial coro-
nary artery was performed using a phased-array,
20-MHz, 3.2-F IVUS catheter (Eagle Eye, Vol-
cano Corporation, Rancho Cordova, California)
that was placed into the distal coronary artery after
intracoronary administration of 0.2 mg nitroglyc-
erin and withdrawn to the aorto-ostial junction
using motorized catheter pullback at 0.5 mm/s.
During pullback, grayscale IVUS images were re-
corded, raw radiofrequency data were captured at
the top of the R-wave, and reconstruction of the
color-coded map by an IVUS-VH data recorder
was performed (In-Vision Gold and S5, Volcano
Corporation).
Offline grayscale and IVUS-VH analysis were
performed by: 1) QCU-CMS software (Medis
Medical Imaging Systems) for contouring; 2) pcVHA B B R E V I A T I O N S
A N D A C R O N YM S
ACS acute coronary
syndrome(s)
CSA cross-sectional area
DS diameter stenosis
EEM external elastic
embrane
VUS intravascular ultraso
ACEmajor adverse
ardiac event
Imyocardial infarction
NC nonculprit
SLP substantial lesion
rogression
CFA thin-cap fibroathero2.1 software (Volcano Corporation) for contouring
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S97and VH data output; and 3) qVH software (devel-
oped within the Cardiovascular Research Founda-
tion) for segmental qualitative assessment and data
output.
External elastic membrane (EEM) and luminal
borders were contoured for all recorded frames
(approximately every 0.5 mm in length depending
on the R-R interval). Quantitative IVUS measure-
ments include EEM cross-sectional area (CSA),
luminal CSA, plaque and media (defined as EEM
CSA minus luminal CSA) CSA, and plaque burden
(defined as plaque and media CSA divided by EEM
CSA). The proximal and distal reference segments
were the most normal looking segments (largest
lumen with least plaque) within 5 mm proximal and
distal to the lesion but before a major side branch.
The remodeling index was defined as lesion EEM
CSA divided by mean reference EEM CSA (21).
Radiofrequency IVUS plaque components were
color-coded as dense calcium (white), necrotic core
(red), fibrofatty (light green), or fibrous tissue (dark
green) and reported as CSA and percents of total
plaque area (22).
Deﬁnitions of lesion types. Data were constructed at
3 levels: lesion level, fibroatheroma level, and slice
level. An IVUS lesion was defined as a segment
with 3 consecutive frames with 40% plaque
urden. The lesions were considered separate le-
ions if there was a 5-mm-long normal segment
40% plaque burden) between them.
Lesions were further classified into 5 main types:
) VH TCFA; 2) thick-cap fibroatheroma; 3)
athological intimal thickening; 4) fibrotic plaque;
nd 5) fibrocalcific plaque. Fibroatheromas (VH-
CFA and thick-cap fibroatheroma) had 10%
onfluent NC lesions (23).
Statistical analysis. Continuous variables are pre-
ented as medians and interquartile ranges and were
ompared using Mann-Whitney U tests. Categor-
cal variables are summarized as absolute values and
ercents and were compared using chi-square or
isher exact tests. Paired statistical comparisons
etween groups were performed using Student
tests. Time-to-event data are presented as Kaplan-
eier estimates. A p value 0.05 was considered
tatistically significant. All analyses were performed
sing SAS version 9.1.3 (SAS Institute Inc., Cary,
orth Carolina).
R E S U L T S
Patient characteristics. From the 697 patients exam-
ned in the PROSPECT study, 72 (10.3%) experi-nced major events related to NC lesions during a
edian follow-up period of 3.4 years. Of them, 44
atients (61%) had events that were attributed to
LP (20% quantitative coronary angiographic DS
ncrease), while 28 patients had events attributable
o NC lesions without SLP. Baseline patient char-
cteristics and laboratory results are listed in Table 1.
omparing patients with NC lesions with and
hose without SLP, age, sex, risk factors, baseline
ipid and metabolic profile, high-sensitivity C-reactive
rotein levels, risk score, and number of culprit
essels were similar.
Angiographic analysis. By angiography, all patients
with NC events had at least 1 angiographically evident
lesion at baseline (30% DS by visual estimate) that
was treated after the index procedure only with con-
temporary medical therapy and not with stent implan-
tation or other percutaneous technique. Overall, the
44 patients with SLP causing NC events had 55
NC-related lesions; the 28 patients without SLP
causing NC events had 46 NC-related lesions. As
shown in Table 2, NC lesions with SLP were less
severe at baseline (median DS 26.4% vs. 53.8%, p 
0.0001) but more severe at the time of the event
(median DS 73.8% vs. 56.0%, p  0.0001) (Fig. 1).
The progression in DS from baseline to follow-up was
statistically significant, however, in the NC lesion
groups both with and without SLP (p  0.0001 in
both groups). There were no significant differences
regarding lesion location, lesion length, or qualitative
morphologies either at baseline or at follow-up be-
tween the two groups.
Grayscale and IVUS-VH analysis. At baseline, IVUS
and IVUS-VH analysis was performed in 52 of 101
lesions (51%) causing NC events during follow-up.
Nonimaged lesions causing NC events were located
in branches or distal vessels, that is, not in the
proximal 6 to 8 cm of the 3 major epicardial vessels
where grayscale and IVUS-VH imaging was per-
formed. All NC event-related lesions with versus
without SLP had a large but comparable plaque
burden (median 68.7% vs. 70.1%, p  0.17) and
nonsignificantly different minimal luminal area
(median 3.7 vs. 4.0 mm2, p  0.60), and the
majority (83.3% vs. 90.9%, p 0.68) were classified
as IVUS-VH fibroatheromas at baseline (Fig. 2).
There were no differences between the two groups
(lesions with vs. without SLP) regarding baseline
grayscale IVUS measurements, quantitative IVUS-VH
analysis, or IVUS-VH phenotype (Table 3).
NC lesion events. As shown in Table 4, the pattern of
events differed significantly between NC lesions with
versus without SLP. There were no deaths in either
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S98group. MIs occurred only in patients with SLP.
Conversely, patients without SLP presented more
commonly with increasing angina leading to
rehospitalization.
Table 5 shows the annual cumulative event rates
according to lesion progression. NC events attrib-
uted to lesions without SLP occurred earlier than
those attributed to lesions with SLP (at 1 year,
45.5% vs. 67.9%, p  0.03; at 2 years, 75% vs.
5.7%, p  0.05; at 3 years, 97.7% vs. 96.4%, p 
0.15). Time-to-event curves for NC lesion–related
MACEs are shown in Figure 3.
D I S C U S S I O N
The major findings of this substudy analysis from
Table 1. Patient Baseline Clinical Characteristics
S
(n 
Age (yrs) 58.5 (5
Men 33 (7
Body mass index (kg/m2) 29.7 (2
Risk factors
Diabetes mellitus 11 (2
Insulin dependent 5 (1
Hypertension 27/43 (6
Hypercholesterolemia 3/41 (5
Family history of CAD 18/36 (5
Current cigarette use 18/43 (4
Prior MI 5 (1
Prior PCI 9 (2
Metabolic syndrome 21 (4
Framingham risk score 7 (6
Clinical presentation
STEMI 24 h 16 (3
NSTEMI 28 (6
Unstable angina 0 (0
Laboratory results
Total cholesterol (mg/dl) 188 (1
LDL cholesterol (mg/dl) 106 (8
HDL cholesterol (mg/dl) 38.8 (3
Triglycerides (mg/dl) 128 (8
Glycosylated hemoglobin 5.85 (5
Estimated creatinine clearance (ml/min) 97.2 (7
hs-CRP, day 0 (mg/dl) 8.2 (3
hs-CRP, day 30 (mg/dl) 1.7 (0
hs-CRP, day 180 (mg/dl) 1.8 (0
Number of culprit vessels
1 28 (6
2 16 (3
Values are median (interquartile range), n (%), or n/N (%).
CAD  coronary artery disease; HDL  high density lipoprotein; hs-CRP  h
infarction; NSTEMI  non–ST-segment elevation myocardial infarction; PCI  p
ST-segment elevation myocardial infarction.PROSPECT are as follows. First, during a medianfollow-up period of 3.4 years, 61% of NC lesion
events were associated with SLP. Second, there
were no NC lesion–related deaths, and MIs oc-
curred only in patients with SLP. Conversely,
patients without SLP presented only with unstable
or increasing angina leading to rehospitalization
and revascularization. Third, compared with NC
lesions with SLP, lesions without SLP became
symptomatic earlier and were more severe at base-
line by angiography, suggesting that they were
significant at the time of the index event. Fourth,
conversely, lesions with SLP became symptomatic
later, were less severe at baseline by angiography but
not by IVUS, and were more severe angiographi-
cally at the time of the event (and with greater
)
Non-SLP
(n  28) p Value
67.7) 54.5 (48.4–66) 0.24
20 (71.4%) 0.74
32.7) 28.1 (24.6–33.6) 0.29
7 (25%) 1.00
) 1 (3.6%) 0.39
) 12/26 (46.2%) 0.18
) 6/20 (30%) 0.06
16/23 (69.6%) 0.14
) 17 (60.7%) 0.12
) 3 (10.7%) 1.00
) 3 (10.7%) 0.35
) 16/27 (59.3%) 0.35
7 (5–9.5) 0.66
) 8 (28.6%) 0.49
) 18 (64.3%) 0.96
2 (7.1%) 0.15
208) 163 (146–192.3) 0.18
38.4) 98 (80.6–119) 0.30
9) 37.5 (35–41) 0.50
177.1) 117.5 (88.6–165) 0.67
.75) 5.7 (5.6–6.2) 0.70
21.5) 99.9 (86.3–128) 0.42
8.4) 8.0 (3–12.5) 0.26
.1) 1.0 (0.7–2.9) 0.40
.7) 1.7 (0.7–4.5) 0.83
) 19 (67.9%) 0.71
) 9 (32.1%) 0.71
ensitivity C-reactive protein; LDL  low-density lipoprotein; MI  myocardial
taneous coronary intervention; SLP  substantial lesion progression; STEMI LP
44
1.8–
5%)
6.6–
5%)
1.4%
2.8%
6.1%
0%)
1.9%
1.4%
0.5%
7.7%
–9)
6.4%
3.6%
%)
54–
3–1
3–4
8.6–
.4–6
5–1
.2–2
.6–5
.8–4
3.6%
6.4%
igh s
ercuangiographic SLP). Last, all lesions causing NC
rig ogression.
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S99events had significant plaque burden (40%) at
baseline. However, there were no differences in
grayscale or IVUS-VH findings comparing le-
sions causing NC events whether or not they had
SLP.
Coronary atherosclerotic lesion progression is neither
linear nor predictable (10,24). In patients with
ACS, angiographic percent DS often increases
suddenly because of plaque rupture and thrombus
formation (10,24,25). Such plaques have well-
defined histopathological characteristics and are
usually termed “vulnerable” or “unstable,” have a
tendency toward acute disruption and increased
thrombogenicity, and are also the sites of intense
inflammatory activity (6,26). In the present study,
NC events associated with SLP occurred in lesions
that were relatively mild at baseline (angiographic
median DS 26.4%; interquartile range: 13.2% to
40.2%) and, importantly, were responsible for all
Table 2. Baseline and Follow-Up Angiographic Variables and Th
SLP
(n  55)
QCA measurements of angiographic
NC lesions
RVD (mm) 2.5 (2–3)
MLD (mm) 1.7 (1.37–2.24)
DS (%) 26.4 (13.2–40.2)
Lesion length (mm) 9.9 (6.7–15.7)
Thrombus 0 (0%)
Ulceration 0 (0%)
Aneurysm 0 (0%)
Intimal ﬂap 0 (0%)
Calciﬁcation 1 (1.8%)
Eccentricity 0 (0%)
Tortuosity 0 (0%)
Angulation
Entry angle (°) 14 (9–22)
Exit angle (°) 14 (7–19)
Maximal angle (°) 20 (13–25)
Bifurcation
Side branch present 7 (12.7%)
DS of side branch (%) 13.1 (6.6–40.5)
Lesion location
LM 2 (3.6%)
LAD (or branches) 14 (25.5%)
LCX (or branches, including ramus) 16 (29.1%)
RCA (or branches) 23 (41.8%)
Branches 19 (34.5%)
Values are median (interquartile range) or n (%).
DS  diameter stenosis; LAD  left anterior descending coronary artery; LCX
applicable; NC  nonculprit; QCA  quantitative coronary angiography; RCA cases of MI. However, IVUS measurements inthese lesions showed a substantial baseline plaque
burden of 68.7% (interquartile range: 62.5% to
70.4%), indicating that these were significant
plaques but in many cases were not associated with
angiographic luminal compromise, because of pos-
itive remodeling or the inaccuracies of angiography,
which can underestimate lesion severity (27).
Therefore, these lesions that appeared mild by
angiography were not mild lesions. Previous studies
have shown that positive remodeling is a risk factor
for plaque vulnerability and major adverse coronary
events, is more common in lesions associated with
unstable syndromes, and is marker for greater bio-
logic activity (28).
Angiographically, lesions associated with acute
coronary events often have “complex” characteris-
tics, consisting of irregular borders, overhanging
edges, and intracoronary thrombi (26); these char-
acteristics in patients treated conservatively have
Changes of NC Lesions
line Follow-Up
on-SLP
n  46) p Value
SLP
(n  55)
Non-SL
(n  46
(2–3.1) 0.62 2.49 (2.02–2.9) 2.3 (2.07–2
(0.8–1.6) 0.0001 0.69 (0.5–1.1) 1 (0.82–1
(38–61.6) 0.0001 73.8 (60.3–80.2) 56 (51.8–6
(7.7–16.9) 0.38 10.1 (8.2–14.3) 11.1 (7–14.9
(0%) NA 1 (1.8%) 0 (0%)
(0%) NA 1 (1.8%) 0 (0%)
(0%) NA 1 (0%) 1 (2.2%)
(0%) NA 0 (0%) 0 (0%)
(2.2%) 1.00 1 (1.8%) 1 (2.2%)
(0%) NA 0 (0%) 2 (4.3%)
(0%) NA 0 (0%) 0 (0%)
(7–25) 0.71 22 (12–26) 18 (12–25
(5–17) 0.52 15 (9–23) 10 (6–23)
(15–25) 0.76 25 (16–29) 24 (15–31
(15.2%) 0.72 11 (20%) 8 (17.4%
(8.3–53.1) 0.67 38.9 (11.2–80.2) 28.8 (3.7–55
(0%) 0.50 2 (3.6%) 0 (0%)
(39.1%) 0.14 14 (25.5%) 18 (39.1%
(34.8%) 0.54 16 (29.1%) 16 (34.8%
(26.1%) 0.10 23 (41.8%) 12 (26.1%
(45.7%) 0.26 19 (34.5%) 21 (45.7%
ft circumﬂex coronary artery; LM  left main coronary artery; MLD  minimal lum
ht coronary artery; RVD  reference vessel diameter; SLP  substantial lesion preir
Base
N
(
P
) p Value
2.3 .93) 0.94
1.15 .40) 0.004
53.8 6.1) 0.0001
12.5 ) 0.82
0 1.00
0 1.00
0 0.46
0 NA
1 1.00
0 0.20
0 NA
18 ) 0.63
13 0.31
18 ) 0.68
7 ) 0.74
22.4 ) 0.31
0 0.50
18 ) 0.14
16 ) 0.54
12 ) 0.10
21 ) 0.26
 le inal diameter; NA  notbeen associated with a rapid increase in severity and
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S100the development of acute events compared with
smooth lesions (29–31). However, these studies
were performed before the routine interventional
management of lesions causing ACS. In the present
study, these complex features were rarely present in
NC lesions from which future MACEs arose.
Nonetheless, 10.3% of patients developed unantic-
ipated NC lesion–related events within 3 years,
Figure 1. Baseline and Follow-Up Angiography
Angiographic diameter stenosis (DS) percent for each nonculprit ev
(SLP) group (left) and the non-SLP group (right).
Figure 2. 2 Patients With NC Events: 1 With and 1 Without SLP
Middle left anterior descending coronary artery (LAD) lesion (*) (A)
(NC) event (C). The baseline minimal luminal area (MLA) was 4.0 m
(B). Proximal LAD lesion (asterisk) (D) without SLP, which caused an
classiﬁed as a TCFA (E). The asterisk represents the lesion.usually at the site of an angiographically innocuous
appearing mild lesion, 61% of which also met our
definition for SLP.
Conversely, NC events without SLP in the
present study occurred in the setting of angio-
graphically borderline lesions at baseline, signifi-
cantly more severe than those with SLP (median
DS 53.8% vs. 26.4%, p  0.0001) but still angio-
at baseline and follow-up for the substantial lesion progression
substantial lesion progression (SLP), which caused a nonculprit
and the lesion was classiﬁed as a thin-cap ﬁbroatheroma (TCFA)
event (F). The baseline MLA was 2.6 mm2, and the lesion wasentwith
m2,
NC
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S101graphically intermediate in severity despite a me-
dian plaque burden by IVUS of 70.1% (interquartile
range: 65% to 74.7%). Thus, these lesions were
more severe at baseline than suggested by angiog-
raphy. This contention is supported by the shorter
time to NC events in the setting of non-SLP
compared with SLP. Physiologic lesion assessment
may be a superior technique to assess ischemia-
producing lesions requiring revascularization than
IVUS. Although previous studies have focused on
the use of physiologic lesion assessment to defer
interventions in nonischemia-producing lesions
that would otherwise be treated (32,33), the present
data suggest a potentially equally important role in
identifying ischemia caused by anatomically inter-
mediate lesions for which intervention would oth-
erwise be deferred. Of note, however, even in the
NC lesions we classified as not having SLP, there
was significant disease progression from baseline to
the time of event, suggesting that it was not
merely the severity of the initial stenosis that
Table 3. Baseline Grayscale IVUS and IVUS-VH Variables
Lesion length (mm) 19
VH phenotype
Any FA (TCFA or ThCFA) 2
TCFA 1
ThCFA 1
PIT
Fibrotic plaque
Fibrocalciﬁc plaque
MLA site
Distance from ostium to lesion MLA site (mm) 26
EEM area (mm2) 12
Luminal area (mm2) 3
P&M area (mm2) 8
Plaque burden (%) 68
Remodeling index 0
Necrotic core (%) 1
DC (%) 4
FF (%) 10
FT (%) 6
Volumetric analysis (%)
Necrotic core 15
DC 5
FF 14
FT 58
Values are median (interquartile range) or n (%).
DC dense calcium; EEM external elastic membrane; FA ﬁbroatheroma; FF
area; NA  not applicable; P&M  plaque and media; PIT  pathologic intima
ThCFA  thick-cap ﬁbroatheroma; VH  virtual histology.resulted in the NC event.In earlier long-term follow-up studies, risk fac-
tors and local coronary anatomy were predictors of
stenosis progression (34,35). In a study from the
National Heart, Lung, and Blood Institute in which
IVUS parameters were not assessed, younger pa-
tient age, unstable clinical presentation, and overall
severity of angiographic coronary artery disease
were proposed as predictors of substantial coronary
stenosis progression (36). In addition, newer studies
suggest a correlation between temporal changes in
plaque composition and circulating biomarkers
(37,38). However, in the present larger study, there
were no differences between the plaques with versus
without SLP regarding patient age, risk factors, and
serologic predictors including, high-sensitivity
C-reactive protein levels.
The classic vulnerable plaque has most frequently
been pathologically characterized as a TCFA (7).
However, in the present IVUS-VH study, half of
the lesions responsible for NC events with or
without SLP were not characterized by IVUS-
LP
30)
Non-SLP
(n  22) p Value
3.2–36.2) 27.3 (22–40.5) 0.17
3.3%) 20 (90.9%) 0.68
0%) 11 (50%) 1.00
3.3%) 9 (40.9%) 0.58
3.3%) 2 (9.1%) 1.00
%) 0 (0%) NA
.3%) 0 (0%) 1.00
2.9–40.5) 29.6 (16.5–52.6) 0.60
.7–15.9) 12.5 (10.87–16.11) 0.39
.3–4.5) 4.0 (3.24–5.17) 0.60
.6–10.8) 9.0 (7.1–12.1) 0.30
2.5–70.4) 70.1 (65–74.7) 0.17
.8–1.0) 0.9 (0.8–1.0) 0.69
.7–26.1) 12.8 (7.1–24.5) 0.53
.2–11.4) 3.4 (2.0–6.4) 0.58
.4–19.5) 16.7 (6.7–25.2) 0.51
2.8–69.4) 61 (58–66.8) 0.95
.1–21.5) 14.1 (8.8–23.4) 0.89
.5–13.5) 6.5 (2.7–9.2) 0.83
.9–21.5) 17.8 (10.9–24.3) 0.46
4.0–67.5) 59.8 (54.9–65.4) 0.93
brofatty; FT ﬁbrotic; IVUS intravascular ultrasound; MLAminimal luminal
kening; SLP  substantial lesion progression; TCFA  thin-cap ﬁbroatheroma;S
(n 
.2 (1
5 (8
5 (5
0 (3
4 (1
0 (0
1 (3
.8 (1
.9 (8
.7 (3
.4 (5
.7 (6
.9 (0
5 (9
.9 (2
.4 (7
1 (5
.3 (9
.9 (2
.3 (8
.8 (5
 ﬁ
l thicVH as VH TCFAs. There are a number of
Abbreviations as in Table
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S102potential explanations. First, recent studies have
shown that coronary artery lesion phenotype is
highly dynamic. New VH TCFAs can develop
from pathological intima thickening or thick-cap
Table 4. Overall Number and Types of Events During a Median
SL
(n 
NC lesion MACEs
Composite MACEs 44 (10
Cardiac death, cardiac arrest, or MI 6 (14
Cardiac death 0 (0%
Cardiac arrest 0 (0%
MI 6 (14
Q-wave MI 2 (4.8
Non–Q-wave MI 4 (9.2
Rehospitalization 39 (93
Due to unstable angina 15 (45
Due to increasing angina 28 (63
Other NC lesion events
Revascularization (PCI or CABG) 44 (10
Due to MI 6 (14
Due to unstable angina 14 (44
Due to increasing angina 28 (63
Stent thrombosis 0 (0%
Death 0 (0%
Values are n (%).
CABG coronary artery bypass graft; MACEmajor adverse cardiac event; MI
coronary intervention; SLP  substantial lesion progression.
Over Time According to Lesion Progression
MACEs at 1 Yr
SLP
(n  20)
Non-SLP
(n  19) p Value
SLP
(n  33
20 (45.5%) 19 (67.9%) 0.03 33 (75%)
ac arrest, or MI 2 (4.5%) 0 (0%) 0.26 3 (6.9%
0 (0%) 0 (0%) NA 0 (0%)
0 (0%) 0 (0%) NA 0 (0%)
2 (4.5%) 0 (0%) 0.26 3 (6.9%
0 (0%) 0 (0%) NA 0 (0%)
2 (4.5%) 0 (0%) 0.26 3 (6.9%
18 (40.9%) 19 (67.9%) 0.01 30 (68.2%
ngina 6 (13.6%) 4 (14.3%) 0.94 11 (25.3%
angina 12 (27.3%) 16 (57.1%) 0.007 21 (47.7%
ents
I or CABG) 20 (45.5%) 16 (57.1%) 0.20 22 (75.0%
2 (4.5%) 0 (0%) 0.26 3 (6.9%
ngina 6 (13.6%) 4 (14.3%) 0.94 11 (25.3%
angina 12 (27.3%) 13 (46.4%) 0.07 21 (47.7%
0 (0%) 0 (0%) NA 0 (0%)
0 (0%) 0 (0%) NA 0 (0%)4.fibroatheroma, indicating that the original phe-
notype at baseline may evolve (39). This is likely
given that thick-cap fibroatheromas were inter-
mediate in risk between TCFAs and nonfibro-
low-Up Period of 3.4 Years
Non-SLP
(n  28) p Value
28 (100%) 0.15
0 (0%) 0.053
0 (0%) NA
0 (0%) NA
0 (0%) 0.053
0 (0%) 0.29
0 (0%) 0.11
28 (100%) 0.009
6 (23.6%) 0.30
24 (100%) 0.004
23 (100%) 0.59
0 (0%) 0.053
5 (19.6%) 0.23
19 (100%) 0.24
0 (0%) NA
0 (0%) NA
yocardial infarction; NA not applicable; NC nonculprit; PCI percutaneous
ACEs at 2 Yrs MACEs at 3 Yrs
Non-SLP
(n  24) p Value
SLP
(n  43)
Non-SLP
(n  27) p Value
24 (85.7%) 0.053 43 (97.7%) 27 (96.4%) 0.15
0 (0%) 0.17 6 (14.1%) 0 (0%) 0.053
0 (0%) NA 0 (0%) 0 (0%) NA
0 (0%) NA 0 (0%) 0 (0%) NA
0 (0%) 0.17 6 (14.1%) 0 (0%) 0.053
0 (0%) NA 2 (4.8%) 0 (0%) 0.29
0 (0%) 0.17 4 (9.2%) 0 (0%) 0.11
24 (85.7%) 0.02 38 (86.4%) 27 (96.4%) 0.01
5 (18.2%) 0.53 14 (32.3%) 6 (23.6%) 0.42
21 (76.2%) 0.005 28 (63.6%) 23 (84.1%) 0.007
20 (71.4%) 0.60 43 (97.7%) 22 (80.4%) 0.50
0 (0%) 0.17 6 (14.1%) 0 (0%) 0.053
4 (14.3%) 0.33 13 (30%) 5 (19.6%) 0.34
17 (61.3%) 0.14 28 (63.6%) 18 (65.6%) 0.35
0 (0%) NA 0 (0%) 0 (0%) NA
0 (0%) NA 0 (0%) 0 (0%) NAFol
P
44)
0%)
.1%)
)
)
.1%)
%)
%)
.2%)
.8%)
.6%)
0%)
.1%)
%)
.6%)
)
)
mTable 5. Event Rates
M
)
NC lesion MACEs
Composite MACEs
Cardiac death, cardi )
Cardiac death
Cardiac arrest
MI )
Q-wave MI
Non–Q-wave MI )
Rehospitalization )
Due to unstable a )
Due to increasing )
Other culprit lesion ev
Revascularization (PC )
Due to MI )
Due to unstable a )
Due to increasing )
Stent thrombosis
Death
Values are n (%).
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S103atheromas (40). Second, in the present study, the
time to SLP events was longer than the time to
non-SLP events, presumably indicating more
time for phenotype evolution into a TCFA that
most likely then ruptured and thrombosed, caus-
ing SLP. Third, in contrast, not all TCFAs lead
to events or are even associated with SLP.
TCFAs can rupture silently or heal spontaneously
without causing events. Finally, not all TCFAs
rupture. There are other lesion types responsible
for events, such as surface erosions in the absence
of cap disruption or unruptured TCFAs with
superimposed thrombosis (41).
Study limitations. First, there was no control group
f lesions that progressed without causing clinical
vents. Angiographic follow-up was not performed
n asymptomatic patients in PROSPECT, so as not
o disturb the natural history of the disease, as has
appened in restenosis studies.
Second, the axial resolution of IVUS used in this
tudy was approximately 150 m, whereas the
athologic definition of TCFA requires a cap thick-
ess 65 m. Nonetheless, the identification of a
H TCFA by radiofrequency IVUS has prognostic
alue for the site-specific identification of lesions
ikely to cause future MACEs (11).
Third, IVUS was performed per protocol in
he proximal 6 to 8 cm of the coronary tree but
Figure 3. Time-to-Event Curves for NC Lesion–Related MACEs in
Major adverse cardiac events (MACEs) included cardiac death, cardi
progressive angina. The 3-year cumulative MACE rates are shown (K
(NC) lesion–related events, 6.4% with substantial lesion progressionnfrequently in distal vessels and branches. All i01 angiographic NC MACE-related lesions had
aseline angiography, but only 52 arose from
esions in the left main, proximal, or mid left
nterior descending or circumflex coronary artery,
r proximal to distal right coronary arteries that
ere imaged at baseline by grayscale IVUS and
VUS-VH.
Fourth, the IVUS catheter may at times have
een tightly wedged within the atherosclerotic le-
ion, precluding accurate assessment of plaque bur-
en or luminal area; this may in part explain the
iscrepancy between angiographic and IVUS lesion
everity. It is unlikely that this would have affected
H phenotype classification, however.
Fifth, there were relatively few MIs, and all
eaths were classified as indeterminate given the
bsence of follow-up angiography. Nonetheless,
any of the patients with unstable or progressive
ngina had clear evidence of angiographic plaque
upture, with the vessel likely remaining patent
ecause of their intense pharmacologic treatment
nd close clinical follow-up with early treatment.
Sixth, classification of these 2 types of NC lesions
ccurred only at the end point; the 2 types of NC
esions do not represent types of disease that were
dentified at baseline.
Finally, IVUS-VH was not routinely performed
t follow-up, which might have provided additional
7 Patients With Acute Coronary Syndromes
rrest, myocardial infarction, or rehospitalization for unstable or
an-Meier estimates). The 3-year rates were 11.7% for all nonculprit
P), and 6.7% without SLP.69
ac a
aplnsights into plaque compositional evolution.
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S104C O N C L U S I O N S
The present study confirms the unpredictable char-
acter of disease progression in NC lesions, demon-
strating implications related to the type of progres-
sion. Approximately 60% of NC events exemplified
the classic notion of vulnerable plaque (SLP of
angiographically mild lesions), while 40% were atgional Observations to Study Pre-
1
1
1
1
1
1
1
1
Circulation 2003;1treated significant disease with significant but less
change in angiographic severity over time. NC
lesions that progressed rapidly were more likely to
result in severe cardiovascular events, including MI.
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